Genotypic characterization of human immunodeficiency virus type 1 isolated from vertically infected children with antiretroviral therapy experience

Pediatric Infectious Disease Journal

Volumn 19, Issue 4, 2000, Pages 363-364

  Johann Liang, Rosemary ^a   Lee, Sakai E ^a   Fernandez, Aracelis ^a   Cervia, Joseph ^a   Noel, Gary J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antiretrovirals; Genotype; Mutations; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CODON; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS ISOLATION;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CODON; DISEASE TRANSMISSION, VERTICAL; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; MUTATION; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0034001339     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200004000-00025     Document Type: Article

References (11)

1. International AIDS Society. USA Panel on Antiretroviral Therapy for HIV Infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280:78-86.
2. Palumbo PE, Kwok S, Waters S, et al. Viral measurements by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr 1995;126:592-5.
3. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997;336:1337-42.
4. McIntosh K, Shevitz A, Zakhun D, et al. Age and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996;15:1087-91.
5. Hertogs K, DeBethune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates form patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-76.
6. Soriano V, Dietrich U, Villalba N, et al. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997;11:696-7.
7. Tisdale M, Kemp S, Parry N. Rapid in vitro selection of HIV type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-6.
8. Richman D, Havlir-D, Corveil J, et al. Nevirapine resistance mutations of HIV type 1 selected during therapy. J Virol 1994;68:1660-6.
9. Hertogs K, Mellors JW, Schel P. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates [Abstract 395]. In: Proceedings of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1 to 5, 1998.
10. Deeks SG, Smith M, Holodniy M, Kahn J. HIV-1 Protease inhibitors. JAMA 1997;277:145-53.
11. Schinazi R, Larder B, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:129-41.